Key facts
- This page summarizes Bradley S. Galer's Form 3 filing for Rapport Therapeutics, Inc. (RAPP).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Jun 2024, 19:07.
Bradley S. Galer - 06 Jun 2024 Form 3 Insider Report for Rapport Therapeutics, Inc. (RAPP)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- RAPP
- Reported as of
- 06 Jun 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Jun 2024, 19:07:06 UTC
- Prior SEC filing
- 09 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cheryl Gault, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bradley S. Galer filed Form 3 for Rapport Therapeutics, Inc. (RAPP) on 06 Jun 2024.
Change
- Previous filing in this sequence was filed on 09 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RAPP
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 197,426
- Date
- 06 Jun 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RAPP
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,922
- Exercise price
- $1.80
- Footnotes
- F1
RAPP
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,513
- Exercise price
- $9.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the shares underlying this option shall vest and become exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney